Equities

Revenio Group Oyj

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Revenio Group Oyj

Actions
Health CareMedical Equipment and Services
  • Price (EUR)18.06
  • Today's Change-1.54 / -7.86%
  • Shares traded289.17k
  • 1 Year change-39.72%
  • Beta1.2770
Data delayed at least 15 minutes, as of Feb 11 2026 13:51 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Revenio Group Oyj, formerly Done Solutions Oyj, is a Finland-based company primarily engaged in the health technology segment. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. It distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.

  • Revenue in EUR (TTM)109.02m
  • Net income in EUR18.50m
  • Incorporated2001
  • Employees248.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medistim ASA59.03m12.57m351.31m154.0027.869.4723.555.957.797.7936.5622.911.250.76799.674,341,637.0026.7221.9833.0927.1981.2178.6621.3020.322.03--0.048485.046.889.120.00878.1112.5316.89
CellaVision AB71.79m14.48m363.25m236.0025.094.3319.965.066.426.4231.8237.210.72012.026.80--14.5214.7116.2216.9668.5068.3820.1719.852.9725.880.028141.974.949.998.7811.3420.7629.67
COLTENE Holding AG263.46m15.67m364.95m1.18k23.303.6915.831.392.402.4040.2215.131.311.346.40204,684.507.8010.5914.2618.4366.1162.195.957.640.70437.620.360685.663.06-1.7971.310.4306-15.4510.76
IVF Hartmann Holding AG174.51m20.82m379.57m309.0018.252.3914.332.187.927.9266.3960.570.89643.287.88526,221.1010.697.9012.919.6855.7154.0611.939.133.79--0.004248.547.332.8534.0210.78-28.9419.92
Ion Beam Applications SA596.63m17.00m462.71m2.10k26.913.7715.700.77560.56770.567720.174.060.97562.733.28281,693.602.781.5012.034.6431.2134.392.852.150.62097.410.363170.816.7512.01201.573.997.6925.86
Revenio Group Oyj109.02m18.50m522.95m248.0028.284.7822.954.800.69310.69314.084.100.80872.916.94452,352.7013.6514.1115.7517.5371.8670.9616.8820.611.8010.720.103653.127.1915.91-3.2014.6422.935.92
Lumibird SA215.95m10.73m527.97m1.07k49.222.6417.352.440.47750.47759.618.900.50770.95934.42202,198.502.522.513.113.1763.8961.894.974.901.643.160.45830.001.7513.34-20.08-8.3815.27--
RaySearch Laboratories AB (publ)122.17m20.73m528.50m450.0028.376.7611.544.336.396.3937.6926.820.65234.152.843,104,637.0011.072.9616.314.3792.9690.9316.975.801.55--0.30967.9016.629.96149.4932.190.5132--
medmix AG512.34m-6.35m540.14m2.67k--1.1510.131.05-0.1696-0.169611.6010.390.47073.565.86174,403.90-0.49271.27-0.61991.5534.5235.24-1.052.651.101.870.4268140.79-0.55492.84-2,566.67--6.02--
Advanced Medical Solutions Group plc252.68m10.46m556.59m1.50k53.011.8915.972.200.04170.04171.011.170.57582.095.57137,690.002.385.092.635.5252.1955.064.1411.151.553.880.242833.4740.6611.64-55.35-17.818.3610.90
Xvivo Perfusion AB76.83m2.38m569.11m198.00239.722.8563.087.410.79680.796825.7667.100.340.89396.134,101,844.001.053.281.123.5273.8173.863.1010.873.681.830.05570.00-1.2535.19-85.39------
Synektik SA124.89m22.42m601.45m203.0026.8311.3923.814.8211.099.2061.8026.121.2211.183.60--21.9620.1136.1032.6734.9831.4017.9513.601.4142.090.153--9.1640.2951.5870.0228.82--
Arjo AB (publ)1.04bn31.59m664.50m6.94k22.541.014.920.63861.231.2340.3927.380.7044.926.221,584,702.002.143.262.914.8042.5943.423.044.780.84944.190.417948.74-2.593.92-32.93-8.68--2.25
Data as of Feb 11 2026. Currency figures normalised to Revenio Group Oyj's reporting currency: Euro EUR

Institutional shareholders

18.45%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 07 Jan 2026830.78k3.11%
Keskin�inen El�kevakuutusyhti� Ilmarinenas of 31 Dec 2024699.79k2.62%
SEB Wealth Management Finland Ltd.as of 31 Dec 2025658.00k2.47%
Handelsbanken Fonder ABas of 31 Jan 2026476.46k1.79%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025430.86k1.62%
Keskin�inen Ty�el�kevakuutusyhti� Eloas of 31 Dec 2024393.32k1.47%
Financi�re de l'�chiquier SAas of 31 Dec 2024385.37k1.44%
Groupama Asset Management SAas of 31 Jan 2025356.52k1.34%
Case Kapitalf�rvaltning ABas of 30 Jan 2026355.65k1.33%
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 31 Dec 2024336.75k1.26%
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.